ArticleBMC gastroenterology2025
Global, regional, and national burden of inflammatory bowel disease in persons aged 60-89 years from 1992 to 2021.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Global and Regional Burden of Crohn's Disease (1990-2023): A Global Burden of Disease Study Analysis.Cureus · 2026Article
- Assessing disability-adjusted life years (DALY) from multiple medication use and multiple illnesses of older adults in rural Thailand.Aging clinical and experimental research · 2026Article
- Use of Upadacitinib in elderly patients with IBD: a case series.Journal of pharmaceutical health care and sciences · 2026Article
- Review
- Global, Regional, and National Burdens of Inflammatory Bowel Disease in Women of Reproductive Age (15-49 Years) from 1992 to 2021.International journal of women's health · 2025Article
- Global burden of inflammatory bowel disease in children and adolescents, 1990-2021: trends, age-specific patterns and future projections.Frontiers in pediatrics · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe global burden of inflammatory bowel disease (IBD) is increasing, but detailed data on older adults remain scarce.
objectiveThis study describes trends in incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of IBD among individuals aged 60-89 years from 1992 to 2021 at global, regional, and national levels, and forecasts the epidemiological status for 2030.
methodsWe used the Global Burden of Disease (GBD) database, covering 204 countries and territories. Temporal trends were analyzed using Joinpoint regression models. Decomposition analysis assessed the impacts of population growth, aging, and epidemiological changes. The Nordpred model forecasted 2030 incidence, prevalence, mortality, and DALYs of IBD among older adults.
resultsFrom 1992 to 2021, the global age-standardized incidence rate (ASIR) of IBD among older adults increased (AAPC 0.34). Conversely, the prevalence rate (ASPR) slightly decreased (AAPC - 0.04). Both mortality (ASMR) and DALYs significantly declined (AAPC - 0.60 and - 0.49, respectively). High SDI regions had the highest ASIR and ASPR, with Middle SDI regions experiencing the fastest ASIR growth. Population growth accounted for 117.77% of the overall increase in the IBD burden. By 2030, the incidence rate is expected to rise, but prevalence, mortality, and DALYs rates are predicted to decrease.
conclusionThe incidence rate of IBD among older adults is rising, while prevalence, mortality, and DALYs rates are declining. Significant regional variations underscore the need for targeted public health policies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.